期刊
RESEARCH IN VETERINARY SCIENCE
卷 135, 期 -, 页码 143-152出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.rvsc.2021.01.012
关键词
PRRSV; Chimera; Vaccine; K418DM; Safety; Efficacy
资金
- Daesung Microbiological Labs. Co., Ltd. (Uiwang, Republic of Korea)
- KBNP, INC. (Anyang, Republic of Korea)
- KCAV Co., Ltd. (Daejeon, Republic of Korea)
- National Research Foundation of Korea (NRF) - Ministry of Education [2019R1A6A3A13096813]
- Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry (IPET) - Ministry of Agriculture, Food and Rural Affairs (MAFRA) [32000504]
- National Research Foundation of Korea [2019R1A6A3A13096813] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
The chimeric PRRS virus K418DM1.1 is a promising vaccine candidate showing high protective efficacy in both homologous and heterologous challenge studies, along with significant reductions in viremia levels. Field studies also demonstrated lower viremia in vaccinated pigs compared to unvaccinated pigs, suggesting K418DM1.1's effectiveness in real-world scenarios. The safety tests indicated negligible risk of virulence and transmission in both vaccinated and comingled groups, further supporting K418DM1.1 as a good vaccine candidate.
Vaccination is currently the most effective strategy to control porcine reproductive and respiratory syndrome (PRRS). New-generation PRRS vaccines are required to be safe and broadly cross-protective. We have recently created the chimeric PRRS virus K418DM which proved to be a good vaccine candidate under field conditions. In the present study, we designed safety and efficacy tests under experimental and field conditions for further evaluation of K418DM1.1, a plaque-purified K418DM. In the homologous challenge study, K418DM1.1 induced high serum virus neutralization (SVN) antibody titers (i.e., 4.2 log(2) +/- 1.7) at 21 days post-challenge (dpc) and provided protection as demonstrated by the significantly lower levels of viremia at 3 and 7 dpc and significantly lower microscopic lung lesion scores compared to the unvaccinated group. K418DM1.1 was also protective in the heterologous challenge study, with vaccinated pigs showing significantly lower levels of viremia at 14 dpc compared to the unvaccinated pigs. A field study was performed to evaluate the efficacy of K418DM1.1 against heterologous exposure and vaccinated pigs presented significantly lower viremia than unvaccinated pigs. According to the safety test for the examination of virulence reversion, no infectivity was observed in tissue homogenate filtrate both in the vaccinated and comingled groups. Thus, the risk of virulence, as well as transmission, appeared negligible. These overall results indicate that K418DM1.1 is a good vaccine candidate based on its safety and protective efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据